Mastodon Skip to main content

Posts

Showing posts with the label OBI Pharma

Biosion has submitted the IND application for BSI-992, an anti-TROP2 ADC

 Biosion submitted the IND application for BSI-992, a TROP2 ADC, on April 9th, 2024 in China. The TROP2 targeting antibody, discovered by Biosion, was licensed to OBI Pharma in 2021. OBI ADC Technology  OBI Pharma (台灣浩鼎) owns the ex-China right of BSI-992/OBI-992 , with the US FDA clearing  an IND application for a Phase 1/2 Study in Jan 2024. The phase 1 trial in the US is estimated to be completed in 2025Q2. Besides OBI-992, OBI Pharma has also discovered a next-generation anti-TROP2 ADC, OBI-902, using the GlycOBI platform in various drug-antibody ratios (DAR). Furthermore, a BsADC targeting TROP2 and HER2 is currently in the preclinical stage. BSI-992/ OBI-992 OBI-992 is a TROP2-directed antibody-drug-conjugate (ADC) that carries a potent topoisomerase I inhibitor and uses a hydrophilic, enzyme-cleavable linker. Upon binding to TROP2 on the surface of cancer cells, OBI-992 is internalized into the cell and trafficked to lysosomes where the linker is cleaved by cathepsin B, releasin